Two major advances have emerged recently for the treatment of haemophilia B (HB), an X-linked recessive bleeding disorder. The first is the development of extended half-life FIX molecules such as the human FIX-albumin (hFIX-Alb) and hFIX-immunoglobulin-Fc (hFIXFc) fusion proteins. 
cal benefit. 10 However, the risk of such approach is the potential immunogenicity to the amino acid change to create hyperactive variant.
In this study, we investigated if liver-targeted gene transfer with AAV vectors encoding the hFIX-Fc and hFIX-Alb proteins would lead to higher steady-state plasma FIX levels than possible when using the wild-type FIX. Our study shows that hFIX-Alb and hFIX-Fc fusion proteins with procoagulant activity are synthesized following AAV-mediated gene transfer in vitro in human liver cells lines and in vivo in murine liver. Expression of these fusion proteins is, however, lower than that of wild-type FIX. The mechanisms limiting expression of the fusion proteins were explored to define the underlying obstacles.
| MATERIAL AND ME THODS

| Construction and production of viral vectors
We designed a transgene expressing human FIX (hFIX) fused to mature albumin cDNA through FIXa-or FVIIa-tissue factor (TF) complex-cleavable linker previously described 1 under the control of our previously described small liver-specific LP1 promoter. 11 A pUC57
cloning vector containing 201 bp of the 3' end of humanly codonoptimised hFIX (hFIXco) cDNA sequence followed by full linker and mature albumin cDNA sequences, flanked by EcoNI and NheI restriction sites were synthesized (GenScript Biotech Corp., Nanjing, China) and cloned using the Quick ligation™ kit (New England Biolabs.Inc, Hitchin, UK). The control pAV-LP1-hFIXco-STOP-(Alb) vector expressing wild-type hFIX (hFIX-ctrl1) was created by introducing a single nucleotide substitution using Q5 ® site-directed mutagenesis kit (New England Biolabs.Inc) with specific primers, thus inducing a stop codon within the cleavable linker. To obtain pAV-LP1-hFIXcoFc vector expressing hFIX covalently fused to the Fc fragment of human IgG1 (hinge, CH2, and CH3 domains), 2 the hFIX coding region was PCR amplified using Phusion ® High fidelity polymerase (New England Biolabs.Inc) from our pAV-LP1-hFIXco with specific primers introducing an EcoRI restriction sites at the 5'-end of the hFIX cDNA, and allowing the removal of the hFIX stop codon and the introduction of BamHI restriction site. The Fc region of human IgG1 (hinge, CH2, CH3) was extracted from an in-house plasmid using BamHI and MluI. Using 3-way ligation, the hFIXco (no stop codon) and Fc fragments were directionally cloned into our pAV-LP1-hFIXco to form pAV-LP1-hFIXco-Fc. The control vector pAV-LP1-hFIXco-STOP-(Fc)
expressing wild-type hFIX (hFIX-ctrl2) was created by inserting the Fc fragment into pAV-LP1-hFIXco after the stop codon of hFIX using restriction enzymes digestion with BamHI isolated with affinity column chromatography as described previously. 15 The genome titres of rAAV-hFIX vectors were determined by the mean of a validated quantitative polymerase chain reaction (QPCR) assay. 16 
| In vitro assay
Huh-7 cells (ECACC 01042712) were maintained in conditioned media containing 5 µg/mL of vitamin K as described previously 17 and were transiently transfected with 1 µg of pAV-LP1-hFIXco-Alb, pAV-LP1-hFIXco-STOP-(Alb), pAV-LP1-hFIXco-Fc and pAV-LP1-hFIXco-STOP-(Fc) vectors using Fugene ® 6 (Roche, Neuilly-surSeine, France). Huh-7 cells were also transduced in vitro at an MOI of 10 5 vg/cell of all four corresponding ssAAV2/8 vectors, as previously reported. 18 Twenty-four hours conditioned media were collected as previously described 19 and assayed for FIX:Ag and FIX:C levels, and SDS-PAGE followed by immunoblotting. The intra cellular secretory traffic of hFIX-ctrl1, rFIX-Alb, rFIXFc proteins was analysed using various protease inhibitors and inhibitor of cellular protein transport diluted in 0.02% ethanol as described elsewhere.
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Results were expressed as a percentage of values obtained with control culture medium containing 0.02% ethanol. 
| Mice, tail-vein injection and blood collection
| Expression of hFIX constructs in mouse liver cells
Experimental mouse livers were harvested at the time of sacrifice for genomic DNA isolation using DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA, USA). Vector genome copy number in mouse liver was determined by QPCR as described previously. 
| Factor IX detection and measurement
FIX:Ag levels were determined using either human FIX specific ELISA as described previously, 18, 20 
| Statistical analysis
Significant differences among groups were analysed via the non-parametric Mann-Whitney test. Analysis was performed in GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Results are expressed as mean ± standard error to mean (SEM). A P-value of <0.05 was considered statistically significant.
| RE SULTS
| rAAV vector genomes direct low expression of hFIX-fusion proteins in vitro
The albumin and human Fc fragments were cloned in-frame and seven-to eightfold lower than hFIX-ctrl1 9.18% (±0.48; P < 0.0001).
The hFIX-Alb recombinant protein, Idelvion ® , was used as control in the same ELISA and was detected at the expected antigen value, indicating that the lower FIX:Ag levels for the hFIX-fusion proteins on ELISA were not due to changes in conformation of the engineered proteins affecting detection. 21 The activity to antigen ratio of the fusion proteins was ~1:1 suggesting that the fusion proteins were fully functional ( Figure 1C ).
Next, we produced and purified single-stranded AAV8 cap- 
| Evaluation of AAV vectors encoding hFIXfusion proteins in vivo
To evaluate the hFIX-fusion proteins in vivo, adult male C57BL/6 Vector genome copy number in mouse liver did not show a significant difference in proviral DNA in the hFIX-Fc cohort when compared to hFIX-ctrl2 (13.9 ± 5.2 vg/cell and 24 ± 2.7 vg/cell, respectively; P = 0.100; Figure 2B ). In contrast, the copy number for hFIX-Alb proviral DNA in the livers of hFIX-Alb cohort was significantly higher when compared to hFIX-ctrl1 (61.7 ± 7.9 vg/cell vs 16 ± 5.7 vg/cell; P = 0.0286; Figure 2B ). This most likely reflected an underestimation of the hFIX-Alb vector titre, leading to administration of a higher vector dose than planned.
To determine if the reduced expression from AAV2/8-hFIX-Alb or -hFIX-Fc was due to inefficient transcription, we performed RNA analysis on liver tissue samples. The mRNA levels present in the hFIX-Alb cohort were lower compared to control samples, potentially suggesting altered transcription of the hFIX-Alb cDNA. There was a trend towards higher mRNA levels in the hFIX-Fc cohort compared to the control samples ( Figure 2C ). This may indicate inefficient translation, protein misfolding and degradation, increased mRNA stability or inefficient secretion of the fusion construct.
| Low expression of hFIX-fusion proteins following gene transfer may be due to poor secretion from murine hepatocytes
Limited immunoprecipitation studies of murine liver cell lysates showed that hFIX-Fc protein was present at relatively high levels within the hepatocytes when compared to controls ( Figure 3A ). This 
| D ISCUSS I ON
The treatment of HB is undergoing substantial changes, with the ap- In the knowledge that hFIX-Fc and hFIX-Alb recombinant proteins were amenable to production at scale, we set out to evaluate these long-acting hFIX-fusion proteins in the context of AAV gene regions of genes including the globin genes. 23 The possibility that endosome with a quicker degradation rate, 24 or increased the level of misfolded hFIX-Fc protein within the cell resulting in elevated endoplasmic reticulum stress and a higher apoptotic rate. 25 These data suggest that the autophagy-lysosome pathway, involved in the intracellular protein quality control 26 by removing large misfolded proteins and proteins aggregates, 27 is activated in liver cells expressing hFIX-Fc fusion proteins. 28 This hypothesis is in accordance with the propensity of Fc fusion proteins to form protein aggregates, 28 which is mostly induced by hydrophobic interactions. 29 Indeed, it has been
shown that the coupling of the Fc region to the hFIX resulted in a difference in hydrogen atom exposition of residues 408-414, 30 which potentially favoured hydrophobic interactions and subsequent formation of hFIX-Fc fusion protein aggregates.
Our hypothesis, therefore, is that the lower plasma circulating levels of the hFIX-fusion proteins is likely due to inefficient secretion of these proteins from hepatocytes when compared to wild-type hFIX protein. There are reports of mutations within FIX or factor VIII (FVIII) genes leading to changes in protein configuration and poor secretion from the producer cells. 19, 31 The role of PACE/furin expression could also be considered as a potential limiting underlying mechanism for low hFIX-fusion protein secretion. 32, 33 It is intriguing to speculate whether similar observations are made during the largescale manufacture of these proteins as recombinant concentrates, though it is possible that changes in secretion pattern of hFIX-fusion protein may not be detected if the producer cells are lysed prior to purification of the hFIX-fusion protein.
One limitation of our study is that we did not inject HB mice, higher specific activity compared to wild-type hFIX, 9 in an AAV vector, could result in sustained mean steady-state FIX:C of about 34%.
Interestingly, the FIX:Ag expression levels, in patients who had a negative status for cross-reactive material, were similar to that observed in the previous clinical trial sponsored by UCL/St Jude.
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| CON CLUS ION
In conclusion, our study shows that hFIX-fusion proteins, though synthesized by hepatocytes appropriately, are not efficiently secreted, thus making them unsuitable for use in gene therapy approaches, despite their extended half-life as recombinant protein replacement therapies. Our preliminary data suggest that the intracellular trafficking of hFIX-Alb and hFIX-Fc may differ but further studies are required to elicit the mechanism behind these observations.
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